<DOC>
	<DOC>NCT03092934</DOC>
	<brief_summary>This two-part study consists of a Phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a Phase 2 portion in up to 3 cohorts with either Small Cell Lung Cancer, Breast Cancer and/or one other solid tumor type</brief_summary>
	<brief_title>A Study of AK-01 in Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Have received at least 1 but no more than 4 prior systemic therapies Have adequate organ function Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale Have estimated life expectancy greater than or equal to (â‰¥)12 weeks Have fully recovered from radiation therapy or surgery, and are recovering from any acute adverse effects of other cancer therapies Have discontinued all chemotherapy, investigational therapy, molecularlytargeted therapy, and cancerrelated hormonal therapy at least 14 days prior, biologic or immunotherapeutic therapy at least 21 days prior, or mitomycinC or nitrosoureas at least 6 weeks prior Female participants with reproductive potential agree to use 2 forms of highly effective contraception during the study and for the following 3 months Male participants must use a barrier method of contraception during the study and for the following 3 months Phase 1 Have evidence of a solid tumor that is locally advanced and/or metastatic(excluding primary brain tumor) Phase 2 Have disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 Have evidence of a solid tumor that is locally advanced and/or metastatic, and in: Small Cell Lung Cancer (SCLC), must have failed platinumcontaining therapy Breast Cancer, be Estrogen Receptor positive and/or Progesterone Receptor positive, but Human Epidermal Growth Factor Receptor 2 (HER2) negative, and must have failed a hormone therapy and a Cyclindependent kinase 4/6 (CDK4/6) inhibitor Have a solid tumor type that has been approved by the sponsor Have symptomatic central nervous system (CNS) metastasis (unless asymptomatic and not current receiving corticosteroids) or a primary tumor of the CNS Have a medical condition that precludes participation (swallowing disorder, organ transplant, pregnant or nursing, HIV, active Hepatitis B or C, cardiac disease, history of major surgery in upper gastrointestinal (GI) tract or GI disease, hypokalemia, hypomagnesaemia or hypocalcaemia that cannot be controlled)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Small Cell Lung Carcinoma</keyword>
</DOC>